- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
BioCorRx announced the completion and beta launch of its proprietary mobile application for use by licensed behavioral specialists and individuals in treatment for opioid and alcohol use disorders.
BioCorRx (OTCQB:BICX) announced the completion and beta launch of its proprietary mobile application for use by licensed behavioral specialists and individuals in treatment for opioid and alcohol use disorders.
As quoted in the press release:
The application is scheduled to be made available in the Apple App Store and Google Play September 21, 2017.
In April, the Company entered into an agreement with DynamiCare Health™, Inc. to develop a co-branded mobile application to support patients participating in medication-assisted treatment (MAT) programs for the treatment of alcohol or opioid use disorder and specifically receiving long-term naltrexone treatment.
The mobile application, DynamiCare Rewards™ with BioCorRx CBT, is designed to offer patients a self-guided (yet supervised by licensed professionals), interactive version of BioCorRx’s proprietary, naltrexone specific, Cognitive Behavioral Therapy (CBT) program.
Click here to read the full press release.
Source: www.marketwired.com
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.